Results 121 to 130 of about 25,289 (245)
Background LCZ696 (sacubitril/valsartan) antagonizes the renin–angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP‐generated cGMP may be a more ...
Timothy C. R. Prickett +5 more
core +1 more source
Comprehensive Physiology, Volume 16, Issue 5, October 2026.Pulmonary hypertension is driven by dynamic crosstalk beyond the physical connection between the heart and lung, involving neurohormonal systems, immune pathways, and peripheral organs. This review highlights how multisystem signaling contributes to disease progression and may reveal new diagnostic and therapeutic targets.
Alejandro A. Vega +4 more
wiley +1 more source
Drug Design, Development and Therapy, 2014 Jieon Lee,1,* Howard Lee,2,* Kyungho Jang,1 Kyoung Soo Lim,3 Dongseong Shin,1 Kyung-Sang Yu11Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Clinical Trials ...
Lee J +5 more
doaj
A drug safety evaluation of valsartan
, 2011 INTRODUCTION: Angiotensin receptor blockers (ARBs) as a class are generally considered safe and better tolerated than other antihypertensive drugs.
FOGARI, ROBERTO, Zoppi A.
core
Effects of sacubitril-valsartan on aging-related cardiac dysfunction [PDF]
Heart failure (HF) remains a huge medical burden worldwide, with aging representing a major risk factor. Here, we report the effects of sacubitril/valsartan, an approved drug for HF with reduced EF, in an experimental model of aging-related HF with ...
Donniacuo, Maria +18 more
core +1 more source
SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic +4 more
wiley +1 more source
Sublingual valsartan in hypertensive urgency
, 2001 The objective of this study was to assess the effect of sublingual valsartan in a group of patients with hypertensive urgency. Forty-one patients with hypertensive urgency and systolic blood pressure >200 mmHg, diastolic blood pressure >100 mmHg were ...
Nazan Alparslan +3 more
core +1 more source
PLoS ONERenal dysfunction in heart failure increases mortality, limits treatment options and blunts responses to therapy. Angiotensin receptor-blocker and neprilysin inhibitors (ARNI) may preserve renal function by modulating both the renin-angiotensin ...
Kaja Knudsen Bergo +11 more
doaj +1 more source
Journal of Arrhythmia, Volume 42, Issue 5, October 2026.This case report highlights CRT‐D with Bachmann's bundle pacing (BBP) in a patient with severe heart failure and refractory atrial fibrillation. BBP preserved atrioventricular conduction without PR prolongation, maintained left ventricular–only pacing, and was associated with suppression of atrial fibrillation and improvement in left atrial contractile
Yosuke Murase +4 more
wiley +1 more source
The Positive Effect of Sacubitril-Valsartan Treatment on Frontal QRS-T Angle in Patients with Heart Failure [PDF]
Objective: Introducing angiotensin receptor neprilysin inhibitors (ARNI) to daily clinical practice is one of the most important advances in the treatment of heart failure (HF). ARNI is associated with reduced mortality and hospitalization in HF patients
Mehmet Karaca, Evliya Akdeniz
core +1 more source